Clinical Trial Update: Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial comparing pioglitazone and evogliptin for effects on hepatic fibrosis in patients with chronic hepatitis B and type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Hepatitis with Significant Hepatic Fibrosis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Evogliptin (evogliptin)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Yonsei University | Conditions: Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes | Phase 4 | Status: UNKNOWN